NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, called Ron Cohen, the CEO of Acorda Therapeutics (ACOR) , "one of the greatest CEOs" in the biotech industry.
Must Read: 10 Stocks Carl Icahn Loves in 2014
The company's latest acquisition of Civitas for $525 million will help buildout Acorda's portfolio of treatments.
Civitas is "apparently having great success" with its Parkinson's treatment, which is in Phase 3 trials, he said.
Shares of Acorda Therapeutics are up 18% and are "correct in going higher," Cramer concluded, adding that the company is "remarkable."
-- Written by Bret Kenwell in Petoskey, Mich.